OCS biotech catalysts & pipeline

OCULIS HOLDING AG · Data as of 2026-10-25

Upcoming catalysts

Privosegtor — IND submission

2026

This transaction comes at an opportune time, as Privosegtor is advancing rapidly through key regulatory milestones, including the ongoing PIONEER-1 registrational trial for optic neuritis and an expected IND submission for acute MS relapse later this year.

Source filing

Privosegtor — IND submission

2H 2026

Cross-reference optic neuritis IND for new IND submission in MS relapses in 2H 2026

Source filing

Licaminlimab (OCS-02) — Topline data

Late 2026

With Licaminlimab PREDICT-1 trial site activations complete and a third of patients enrolled, we expect to report topline results around year-end.

Source filing

OCS-01 — NDA/BLA submission

Q4 2026

The topline results from both DIAMOND Phase 3 trials are expected in June 2026, with a subsequent New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) planned for Q4 2026 following a positive readout.

Source filing

Privosegtor — IND submission

Q4 2026

Investigational New Drug (IND) submission being prepared for Q4 2026

Source filing

Explore the free biotech catalyst calendar